NCBI GEO standards and services for microarray data
To the editor: The Minimum Information About a Microarray Experiment (MIAME) guidelines are a data content document developed by the Microarray Gene Expression Data (MGED) Society that outlines the information that should be provided when describing a microarray experiment 1 . Many journals and funding agencies have adopted the guidelines, with the aim of facilitating access to the elements of a study that would enable independent evaluation of results. However, the MIAME requirements have been criticized recently 2, 3 . The criticism stems, in part, from different interpretations of the level of detail required to adequately report a microarray experiment and debates as to whether there is a genuine benefit to making microarray data public.
The Gene Expression Omnibus (GEO) database at the US National Center for Biotechnology Information (NCBI) 4 and ArrayExpress at the European Bioinformatics Institute (EBI) 5 are the two major public databases of microarray data. Although they have different designs, both databases support capture of all data elements defined by MIAME. Figure 1 presents a timeline of major landmarks in the evolution of the GEO database, together with concomitant growth in submissions. GEO was launched in 2000, more than a year before the MIAME guidelines were proposed. Because there was not yet a consensus on reporting standards for microarray data, or even an obligation to make microarray data public, GEO initially allowed a minimal level of experimental detail to be supplied. Over the ensuing years, we have continually monitored the needs and requests of end-users and gauged the level of effort submitters were realistically willing to invest in making their data public. We have responded with incremental improvements to database design and curation standards, and we have developed easy-to-generate batch deposit formats that significantly reduce the burden of submission and allow contributors to focus on the content submitted rather than the mechanism of submission.
In June 2005, we released major database revisions that included specific provisions for all MIAME data elements. In 2006, mechanisms for provision of raw data were further streamlined, and several MIAME elements that were previously optional became mandatory. Yet, even with these advances, it is still possible for a submitter to supply data that do not strictly adhere to the MIAME requirements. The difficulty lies in the fact that MIAME is a subjective set of guidelines where the level of detail to report is open to interpretation and, thus, cannot be unequivocally validated or enforced by computational means.
All data submitted to GEO are syntactically validated for correct document structure, organization and provision of basic elements. Next, each submission is inspected by curators for content integrity. GEO curators employ a pragmatic approach; we aim to ensure that sufficient information has been supplied to allow general interpretation of the experiment. Although encouraged, we have been less dogmatic with regard to provision of all-inclusive experimental protocols that would possibly permit practical replication of the entire experiment. Our reasoning is that provision of granulated experimental details adds a significant burden onto the submitter, for (arguably) minimal real benefit for most end-users who are usually less concerned with this level of detail. When content or format problems are identified, curators work with the submitter until the issue is resolved. Submissions lacking critical descriptive elements necessary for overall experiment interpretation are not approved for public release. However, given the large diversity of biological themes, technologies and statistical transformations applied to microarray data, it is impractical for curators either to decisively determine the accuracy and validity of the data or to assess if all relevant information has been supplied. This is where the role of reviewers and editors becomes important.
The GEO database has had mechanisms for anonymous reviewer access to prepublication data since 2003. Over the past several years, authors have occasionally requested curator comment regarding the level of MIAME compliance of their submissions, and we have been happy to offer feedback on areas that Number of GEO submissions Figure 1 Timeline of GEO growth and major landmarks in evolution of GEO database, together with a screenshot of GEO tools that allow users to query, analyze and visualize the data in GEO. It has been challenging to find the optimal balance between submitter effort and the appropriate level of metadata detail to request, all within a rapidly evolving technological and social environment 7 . However, the relative simplicity of the GEO database structure, together with common-sense curation policies that focus on gathering germane MIAME elements, have made it possible for us to develop an extensive suite of utilities that makes the volumes of complex data archived at GEO accessible and easy to use by the research community at large 8 . Ultimately, the value of a database is reflected in how it is used by the community it serves.
C O R R E S P O N D E N C E
In the past month, GEO received approximately one million query hits and over 200,000 file transfer downloads amounting to over 2.5 terabytes of compressed data. Furthermore, it is clear that researchers are applying these data to their own studies, as demonstrated by over 100 recent publications citing data found in GEO to support or otherwise complement their own studies 9 . We view this as testament that the effort involved in making expression data public through GEO is fully justified.
Why the omega-3 piggy should not go to market
To the editor: The paper in your April issue by Lai et al. entitled "Generation of cloned transgenic pigs rich in omega-3 fatty acids" (Nat. Biotechnol. 24, [435] [436] 2006 ) perfectly captures the fundamental problem with American biotech research. That problem is that scientists pursue their research agenda to further scientific knowledge-all well and good-but when the project succeeds they invent problems for which their research results can be marketed as a solution. This unreflective move from 'pure science' to commercialization may end up as biotech's undoing.
The omega-3 pig is just the latest 'product' to follow this pattern. Recall the case of cloned cattle. As science, these projects had value in adding to our understanding of the process of cloning and the mechanisms of reproduction. But the attempt to employ this technology for a marketable product has hit a hurdle. Although the safety data on milk and meat from cloned cattle appear definitive, the US Food and Drug Administration still continues to drag its feet and has failed to lift the moratorium on the release of cloned products into the food supply-after three years. Why? In short, because no one wants to eat them. Of course, it's a longer story than that, but if there were either market demand or a pressing need for this product, that moratorium would have been lifted long ago.
The story of the omega-3 pig has a parallel plot. Early transgenic projects in pigs demonstrated an important proof of concept, but creating omega-3-enhanced pigs seems to come from the "because we can" school of justification. Even if the benefits of dietary omega-3 were incontrovertible (which they're not) 1 , and even if the only sources of omega-3 were animal based (which they aren't), the rationale for creating these genetically modified (GM) pigs is specious at best. Thus, in their paper, Lai et al. write, "The only way to enrich the tissues of mammals with n-3 fatty acids has been dietary provision of n-3 fatty acids. Thus, the food industry must feed animals with flaxseed, fish meal or other marine products. In view of the decline in marine fish stocks and the potential contamination of fish products with mercury and other chemicals, alternative, land-based dietary sources of n-3 fatty acids are needed." What happened to flaxseed?
But you might say of the super-pig, "so we don't need them, and few people are likely to buy them. Why not let market forces decide the fate of this product postcommercialization?" There are four reasons why this pig ought not to go to market.
First, the use of transgenic technology for this application represents the worst type of 'research waste': precious scientific resources of time, mental energy and money that could be used to tackle serious human and environmental threats are being devoted to a frivolous cause. The list of devastating problems begging for a scientific solution include: chronic, genetic and infectious diseases, famine, food and water safety, global warming, the destruction of ecosystems-the list goes on and on. Because this project was supported by public money, including several US National Institutes of Health grants and one from the US National Cancer Institute, it took funding away from other projects that could have been more beneficial.
Second, the one problem we don't have is a shortage of omega-3-even if it turns out to be the nutritional wonder that some tout it being, which is now in doubt 1 . Not only is it found naturally in readily available foods like walnuts, flaxseed and fish, but it can be found in supplements and nutritionally supplemented foods like Smart Balance peanut butter, oil and margarine. We certainly do have a very serious problem of obesity and nutrition in the United States (and increasingly elsewhere), but neither are It has been challenging to find the optimal balance between submitter effort and the appropriate level of metadata detail to request, all within a rapidly evolving technological and social environment.
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